In vivo evaluation of carbon-11-labelled non-sarcosine-based glycine transporter 1 inhibitors in mice and conscious monkeys

Nuclear Medicine and Biology

Volumn 38, Issue 4, 2011, Pages 517-527

  Toyohara, Jun ^a,b   Ishiwata, Kiichi ^b   Sakata, Muneyuki ^b   Wu, Jin ^a   Nishiyama, Shingo ^c   Tsukada, Hideo ^c   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^c CENTRAL RESEARCH LABORATORY   (Japan)

Author keywords

11C SA1; 11C SA2; 11C SA3; Glycine transporter 1; Positron emission tomography

Indexed keywords

2 CHLORO N [[ 1 METHYLPIPERIDIN 2 YL][PHENYL]METHYL] 3 [TRIFLUOROMETHYL]BENZAMIDE C 11; 2 CHLORO N [[1 METHYLPIPERIDIN 2 YL][THIOPHEN 3 YL]METHYL] 3 [TRIFLUOROMETHYL]BENZAMIDE C 11; 2 CHLORO N [[PIPERIDINE 2 YL][THIOPHEN 3 YL]METHYL] 3 [TRIFLUOROMETHYL]BENZAMIDE; 2 CHLORO N [ALPHA (2 PIPERIDINYL)BENZYL] 3 TRIFLUOROMETHYLBENZAMIDE; 2 CHLORO N [PHENYL[PIPERIDIN S YL]METHYL] 3 [TRIFLUOROMETHYL]BENZAMIDE; BENZAMIDE DERIVATIVE; GLYCINE TRANSPORTER 1; LIGAND; N [3 (4 FLUOROPHENYL) 3 (4 PHENYLPHENOXY)PROPYL]SARCOSINE; N [[1 METHYLPIPERIDIN 2 YL][PHENYL]METHYL]THIOPHENE 2 CARBOXAMIDE C 11; N [PHENYL[PIPERIDINE 2 YL]METHYL]THIOPHENE 2 CARBOXAMIDE; NON SARCOSINE BASED GLYCINE TRANSPORTER 1 INHIBITOR C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONSCIOUSNESS; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG UPTAKE; HAPLORHINI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN DEGRADATION; RADIOACTIVITY;

AMIDES; ANIMALS; CARBON RADIOISOTOPES; CONSCIOUSNESS; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HAPLORHINI; LIGANDS; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; RADIOCHEMISTRY; SUBSTRATE SPECIFICITY;

EID: 79955477750     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.11.009     Document Type: Article

References (55)

1. Aragon C., Lopez-Corcuera B. Glycine transporters: crucial roles of pharmacological interest revealed by gene deletion. Trends Pharmacol Sci 2005, 26:283-286.
2. Eulenburg V., Armsen W., Betz H., Gomeza J. Glycine transporters: essential regulators of neurotransmission. Trends Biochem Sci 2005, 30:325-333.
3. Zafra F., Aragon C., Gimenez C. Molecular biology of glycinergic neurotransmission. Mol Neurobiol 1997, 14:117-142.
4. Danysz W., Parsons A.C. Glycine and N-methyl-d-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 1998, 50:597-664.
5. Smith K.E., Borden L.A., Harting P.R., Branchek T., Weinshank R.L. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron 1992, 8:927-935.
6. Borowsky B., Mezey E., Hoffman B.J. Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene. Neuron 1993, 10:851-863.
7. Liu Q.R., Lopez-Corcuera B., Mandiyan S., Nelson H., Nelson N. Molecular characterization of four pharmacologically distinct gamma-aminobutyric acid transporters in mouse brain. J Biol Chem 1993, 268:2106-2112.
8. Kim K.M., Kingsmore S.F., Han H., Yang-Feng T.L., Godinot N., Seldin M.F., et al. Cloning of human glycine transporter type 1: molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene in the human and mouse genomes. Mol Pharmacol 1994, 45:608-617.
9. Zafra F., Aragon C., Olivares L., Danbolt N.C., Gimenez C., Strom-Mathisen J. Glycine transporters are differentially expressed among CNS cells. J Neurosci 1995, 15(5 Pt 2):3952-3969.
10. Zafra F., Gomeza J., Olivares L., Aragon C., Gimenez C. Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS. Eur J Neurosci 1995, 7:1342-1352.
11. Cubelos B., Gimenez C., Zafra F. Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb Cortex 2005, 15:448-459.
12. Bergeron R., Meyer T.M., Coyle J.T., Greene R.W. Modulation of N-methyl-d-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A 1998, 95:15730-15734.
13. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148:1301-1308.
14. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995, 52:998-1007.
15. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996, 3:241-253.
16. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001, 158:1367-1377.
17. Krystal J.H., D'Souza D.C., Petrakis I.L., Belger A., Berman R.M., Charney D.S., et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 1991, 7:125-143.
18. Tsai G., Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 2002, 42:165-179.
19. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., et al. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis in schizophrenia. Arch Gen Psychiatry 2003, 60:572-576.
20. Hashimoto K., Okamura N., Shimizu E., Iyo M. Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs. Curr Med Chem Cent Nerv Syst Agents 2004, 4:147-154.
21. Hashimoto K., Shimizu E., Iyo M. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr Psychiatry Rev 2005, 1:151-163.
22. Hashimoto K. The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs. Clin Psychopharmacol Neurosci 2006, 4:3-10.
23. Vandenberg R.J., Aubrey K.R. Glycine transport inhibitors as potential antipsychotic drugs. Expert Opin Ther Targets 2001, 5:507-518.
24. Sur C., Kinney G.G. The therapeutic potential of glycine transporter-1 inhibitors. Expert Opin Investig Drugs 2004, 13:515-521.
25. Kinney G.G., Sur C. Glycine site modulators and glycine transporter-1 inhibitors as novel therapeutic targets for the treatment of schizophrenia. Curr Neuropsychopharmacol 2005, 3:35-43.
26. Lindsley C.W., Wolkenberg S.E., Kinney G.G. Progress in the preparation and testing of glycine transporter type-1 (GlyT-1) inhibitors. Curr Top Med Chem 2006, 6:1883-1896.
27. Hashimoto K. Glycine transporter inhibitors as therapeutic agents for schizophrenia. Recent Patents CNS Drug Discov 2006, 1:43-53.
28. Hashimoto K. Glycine transporter-1 inhibitors as novel therapeutic drugs for schizophrenia. Cent Nerv Syst Med Chem 2007, 7:177-182.
29. Javitt D.C. Glycine transport inhibitors and the treatment of schizophrenia. Biol Psychiatry 2008, 63:6-8.
30. Javitt D.C. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Discov Devel 2009, 12:468-478.
31. Hashimoto K. Glycine transport inhibitors for the treatment of schizophrenia. Open Med Chem J 2010, 4:10-19.
32. Roche Global Web Site [Homepage on the Internet] Roche reports positive Phase II results with potential first-in-class treatment for the negative symptoms of schizophrenia [Basel, November 10, 2009]. http://www.roche.com/investors/ir_update/inv-update-2009-11-10.htm.
33. Williams D.L., Jennings A., Lewis R., Street L., Paten S. A novel glycine transporter-1 PET tracer: from discovery to clinic. Abstr Neurosci 2008, 885:15.
34. Hamill T.G., Eng W., Jennings A., Lewis R., Thomas S., Wood S., et al. The synthesis and preclinical evaluation in rhesus monkey of [18F]MK-6577 and [11C]CMPyPB, glycine transporter 1 (GlyT1) PET radiotracers. Synapse 2010, in press.
35. Passchier J., Gentile G., Porter R., Herdon H., Salinas C., Jakobsen S., et al. Identification and evaluation of [11C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography. Synapse 2010, 64:542-549.
36. Dargazanle G., Estenne-Bouhtou G., Magat P., Marabout B., Medaisko F., Roger P., et al. Derivatives of N-[phenyl(piperidine-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics. International patent application WO03/089411 A1 2003.
37. Dargazanli G., Estenne-Bouhtou G., Medaisko F., Renones M.C. Derivatives of N-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics. International patent application WO2005/037781 A2 2005.
38. Dargazanli G., Estenne-Bouhtou G., Magat P. Derivatives of N-phenyl(piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics. International patent application WO2005/037792 A1 2005.
39. Kawamura K., Ishiwata K. Improved synthesis of [11C]SA4503, [11C]MPDX and [11C]TMSX by use of [11C]methyl triflate. Ann Nucl Med 2004, 18:165-168.
40. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
41. Atkinson B.N., Bell S.C., De Vivo M., Kowalski L.R., Lechner S.M., Ognyanov V.I., et al. ALX5407: a potent, selective inhibitor of the hGlyT-1 glycine transporter. Mol Pharmacol 2001, 60:1414-1420.
42. Aubrey K.R., Vandenberg R.J. N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor for glycine transport. Br J Pharmacol 2001, 134:1429-1436.
43. Mallorga P.J., Williams J.B., Jacobson M., Marques R., Chaundhary A., Conn P.J., et al. Pharmacology and expression analysis of glycine transporter GlyT-1 with [3H]-(N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl])sarcosine. Neuropharmacology 2003, 45:585-593.
44. Depoortère R., Dargazanli G., Estenne-Bouhtou G., Coste A., Lanneau C., Desvignes C., et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 2005, 30:1963-1985.
45. Mezler M., Hornberger W., Mueller R., Schmidt M., Amberg W., Braje W., et al. Inhibitors of GlyT1 affect glycine transport via discrete binding sites. Mol Pharmacol 2008, 74:1705-1715.
46. Hashimoto K., Nishiyama S., Ohba H., Matsuo M., Kobashi T., Takahagi M., et al. [11C]CHIBA-1001 as a novel PET ligand for α7 nicotinic receptors in the brain: a PET study in conscious monkeys. PlosONE 2008, 3:e3231.
47. Onoe H., Inoue O., Suzuki K., Tsukada H., Itho T., Mataga N., et al. Ketamine increases the striatal N-[11C]methylspiperone binding in vivo: positron emission tomography study using conscious rhesus monkey. Brain Res 1994, 663:191-198.
48. Watanabe M., Okada H., Shimizu K., Omura T., Yoshikawa E., Kosugi T., et al. A high resolution animal PET scanner using compact PS-PMT detectors. IEEE Trans Nucl Sci 1997, 44:1277-1282.
49. Hashimoto K., Tsukada H., Nishiyama S., Fukumoto D., Kakiuchi T., Shimizu E., et al. Protective effects of N-acetyl-l-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine. Neuropsychopharmacology 2004, 29:2018-2023.
50. Ichise M., Toyama H., Innis R.B., Carson R.E. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab 2002, 22:1271-1281.
51. Logan J., Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990, 10:740-747.
52. Jursky F., Nelson N. Developmental expression of the glycine transporters GLYT1 and GLYT2 in mouse brain. J Neurochem 1996, 67:336-344.
53. Lowe J.A., Drozda S.E., Fisher K., Strick C., Lebel L., Schmide C., et al. [3H]-(R)-NPTS, a radioligand for the type 1 glycine transporter. Bioorg Med Chem Lett 2003, 13:1291-1292.
54. Zeng Z., O'Brien J.A., Lemaire W., O'Malley S.S., Miller P.J., Zhao Z., et al. A novel radioligand for glycine transporter. I. Characterization and use in autoradiographic and in vivo brain occupancy studies. Nucl Med Biol 2008, 35:315-325.
55. Searle G.E., Salinas C., Bullich S., Radua J., Herance R., Lopez-Vilanova N., et al. A pseudo-reference region method applied to measurement of GlyT1 occupancy in human brain using [11C]GSK931145 and PET. Neuroimage 2010, 52:S158.